PASADENA, Calif.--(BUSINESS WIRE)--Calando Pharmaceuticals, a leading siRNA therapeutics company and a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR), announced the publication of a study in the Proceedings of the National Academy of Sciences (PNAS), the scientific journal of the NAS. Dr. Mark Davis, professor of chemical engineering at Caltech, and his colleagues at UCLA used Calando’s proprietary RONDEL™ polymer technology for delivering siRNA in mice. Dr. Davis is a founder and Chief Scientific Advisor to Calando and to Insert Therapeutics, Inc., another majority-owned subsidiary of Arrowhead.
